Arix Bioscience investee company strengthens pipeline

Arix Bioscience PLC (LON:ARIX) said an investee company has “in-licensed” an ATR inhibitor programme from one of the worlds leading cancer centres and a venture capital firm.

Artios Pharmas exclusive deal with The University of Texas MD Anderson Cancer Center and ShangPharma Innovation strengthens the companys earlier-stage pipeline focused on the area of DNA damage response.

DDR is a network of cellular pathways that sense, signal and repair DNA lesions.

Surveillance proteins that monitor DNA integrity can activate cell cycle checkpoints and DNA repair pathways in response to DNA damage, to prevent the generation of potentially harmful mutations.

Arix investment director, Jonathan Tobin, who is also an Artios board member, said he was plRead More – Source